PluriCell Biotech

LizarBio Therapeutics, formerly known as PluriCell Biotech, is a Brazilian biotechnology company specializing in the development of regenerative cell therapies derived from induced pluripotent stem cells (iPSCs). Founded in 2013 and headquartered in São Paulo, the company leverages its proprietary 3D cell expansion and differentiation platform to produce high-quality human cells at scale. Initially focused on providing iPSC-derived cells for drug discovery and research, LizarBio pivoted in 2021 to focus on clinical-stage therapeutic programs. Its current pipeline includes lead candidates for the treatment of heart failure using cardiomyocyte grafts and neurological disorders such as Rett Syndrome using astrocyte-based therapies. The company is a pioneer in the Latin American biotech sector and maintains strong ties with the University of São Paulo and international research institutions. LizarBio aims to address incurable diseases by replacing damaged tissues with functional, lab-grown human cells.